Safe prescribing of valproate - containing medicines in male patients

Recent regulations relating to the prescription of valproate-containing medicines to male patients have raised queries about the evidence base relating to potential teratogenic effects in the female partners of male patients. This session considers that evidence base and places it within the context of wider considerations of therapeutics relating to valproate-containing medicines in male patients.

Learning objectives

In this session you will:

• Gain increased understanding of complexities involved in prescribing valproate-containing medicines to male patients
• Gain increased knowledge of evidence base relating to potential teratogenicity of valproate-containing medicines, when prescribed to male patients
• Consider deficits in providing optimal care when prescribing valproate-containing medicines to psychiatric patients.

Speakers

Dr Jonathan Luke Richardson, UK Teratology Information Service, Newcastle

Dr Lance Watkins, Swansea Bay University Health Board, Swansea

Professor David Taylor, South London and Maudsley NHS Foundation Trust, London

Availability

This webinar is part of the Congress webinar 2025 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2025 package can be purchased below.